Overall and relapse-free survival estimates
| . | Overall survival probability (95% CI) . | ||
|---|---|---|---|
| Initial pentostatin . | Crossed over . | Combined . | |
| Overall survival | N = 154 | N = 87 | N = 241 |
| 5-year | 89% (84-94) | 93% (88-98) | 90% (87-94) |
| 10-year | 80% (73-87) | 85% (77-93) | 81% (75-86) |
| Relapse-free survival | N = 117 | N = 56 | N = 173 |
| 5-year | 86% (80-92) | 84% (74-94) | 85% (80-91) |
| 10-year | 66%(55-78) | 69% (56-82) | 67% (58-76) |
| . | Overall survival probability (95% CI) . | ||
|---|---|---|---|
| Initial pentostatin . | Crossed over . | Combined . | |
| Overall survival | N = 154 | N = 87 | N = 241 |
| 5-year | 89% (84-94) | 93% (88-98) | 90% (87-94) |
| 10-year | 80% (73-87) | 85% (77-93) | 81% (75-86) |
| Relapse-free survival | N = 117 | N = 56 | N = 173 |
| 5-year | 86% (80-92) | 84% (74-94) | 85% (80-91) |
| 10-year | 66%(55-78) | 69% (56-82) | 67% (58-76) |
CI indicates confidence interval.